EUROPE SURGICAL SITE INFECTION CONTROL MARKET FORECAST 2024-2032
KEY FINDINGS The Europe surgical site infection control market is evaluated to progress with a CAGR of 4.44% during the forecast period of 2024-2032. The rising prevalence of surgical site infecti... もっと見る
SummaryKEY FINDINGSThe Europe surgical site infection control market is evaluated to progress with a CAGR of 4.44% during the forecast period of 2024-2032. The rising prevalence of surgical site infections (SSIs) is a significant factor driving the growth of the surgical site infection control market in Europe. MARKET INSIGHTS Additionally, increasing research and development activities are anticipated to further support market expansion as advancements in infection prevention techniques and technologies continue to emerge. Key preventive measures, such as general hygiene, hand hygiene practices, appropriate hair removal, antibiotic prophylaxis, and maintaining normothermia, are critical in reducing the incidence of SSIs. These measures contribute directly to the growth of the SSI control market in Europe by enhancing infection prevention protocols and improving patient outcomes. REGIONAL ANALYSIS The Europe surgical site infection control market growth assessment comprises a detailed evaluation of the United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe. According to Public Health England (PHE), surgical site infections (SSIs) accounted for approximately 16% of all healthcare-associated infections (HAIs) in England, making them the third most common type of HAI in the country. The PHE report highlighted an increasing trend in SSIs, particularly among patients undergoing knee prosthesis, large bowel, and cholecystectomy surgeries. The report also identified that nearly half of the pathogens causing SSIs were Enterobacteriaceae and meticillin-sensitive Staphylococcus aureus (MSSA). Further, the financial burden associated with SSIs is substantial, with costs ranging from GBP 2,100 to GBP 10,500 per infection, depending on the complexity of the surgery, and escalating to as much as GBP 20,000 for complex surgeries. To address this issue, the UK government has implemented various preventive measures, including the Surgical Site Infection Surveillance Service managed by England’s Healthcare-Associated Infection and Antimicrobial Resistance Department (HCAI & AMR). This service provides hospitals with protocols and analytical tools to monitor SSIs while accounting for key risk factors. As a result, government efforts in preventing SSIs are expected to stabilize and promote the growth of the SSI control market in the United Kingdom. In France, SSIs are among the most frequent hospital-acquired infections in surgical patients, contributing significantly to mortality, morbidity, and healthcare costs. According to the European Centre for Disease Prevention and Control, the overall incidence rate of SSIs in France is 20% of all surgical procedures. Common surgeries associated with SSIs include coronary artery bypass grafts, cholecystectomies, colon surgeries, cesarean sections, and hip and knee prostheses, among others. France has implemented a national SSI surveillance solution, the RAISIN surveillance system, which has been operational since 1999. This system is structured on a pyramidal organization at local, regional, and national levels and follows standard guidelines established in 1992 by the American Centers for Disease Control and Prevention (CDC)’s National Nosocomial Infections Surveillance (NNIS) system. Hence, the increasing incidence of SSIs in France remains a key driver of growth in the country’s SSI control market, with an incidence rate of approximately one SSI per 100 procedures. SEGMENTATION ANALYSIS The Europe surgical site infection control market segmentation includes procedure, type of infection, end-user, and product. The procedure segment is further classified into laparoscopy, orthopedic surgery, cardiovascular, obstetrics and gynecology, wound closure, plastic & reconstructive surgery, thoracic surgery, microvascular, urology, neurosurgery, and other procedures. Cardiovascular surgery involves heart-related procedures performed to address complications arising from ischemic heart disease, valvular heart disease, and congenital heart defects, including heart transplant surgeries. Given the high prevalence of cardiac diseases globally, the demand for cardiovascular surgical equipment is substantial. Instruments used in these surgeries include clamps, cutting devices, needle holders, retractors, scalpels, vascular dilators, forceps, powered instruments such as sternal saws and sternotomes, internal defibrillator paddles, and specialized valve surgery instruments like hooks, suture holding frames, and valve dilators. Similarly, obstetrics and gynecology surgeries represent a significant revenue stream for surgical equipment manufacturers due to their large-scale performance. These procedures require a diverse range of instruments, including scalpels, speculums, forceps, cannulas, Metzenbaum scissors, curettes, laparoscopic instruments, Veress needles, trochars, catheters, and colposcopes. Market growth in this segment is driven by factors such as the changing lifestyle of women, the prevalence of various gynecological conditions, a growing demand for minimally invasive surgical alternatives to hysterectomy, advancements in gynecological procedures, high healthcare expenditure, and an aging population. COMPETITIVE INSIGHTS Leading players operating in the Europe surgical site infection control market include Belimed AG, bioMérieux SA, GAMA Healthcare, Getinge AB, etc. Belimed AG is a leading global supplier of cleaning, disinfecting, and sterilizing products for the medical and life sciences industries. The company maintains an extensive network of sales subsidiaries and authorized partners, spanning over 80 countries worldwide. Belimed serves a broad customer base, including multinational pharmaceutical manufacturers, local hospitals, and large medical practices. The company also delivers comprehensive products and solutions that go beyond equipment supply, offering additional services such as planning, simulation, validation, and ongoing support. Headquartered in Switzerland, the company has a strong presence across Europe, North America, and China. Table of ContentsTABLE OF CONTENTS1. RESEARCH SCOPE & METHODOLOGY 1.1. STUDY OBJECTIVES 1.2. METHODOLOGY 1.3. ASSUMPTIONS & LIMITATIONS 2. EXECUTIVE SUMMARY 2.1. MARKET SIZE & ESTIMATES 2.2. MARKET OVERVIEW 2.3. SCOPE OF STUDY 2.4. CRISIS SCENARIO ANALYSIS 2.5. MAJOR MARKET FINDINGS 2.5.1. HIGH EMPHASIS ON ENVIRONMENTAL HYGIENE BOOSTS THE SSI CONTROL MARKET 2.5.2. DISPOSABLE AND SINGLE-USE PRODUCTS ARE SHAPING THE SURGICAL INFECTION CONTROL LANDSCAPE 3. MARKET DYNAMICS 3.1. KEY DRIVERS 3.1.1. SURGE IN GERIATRIC POPULATION 3.1.2. INCREASED INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS 3.1.3. IMPLEMENTATION OF REGULATORY GUIDELINES FOR THE PREVENTION OF HOSPITAL-ACQUIRED INFECTIONS 3.2. KEY RESTRAINTS 3.2.1. LACK OF AWARENESS ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS 3.2.2. SURGING MEDICAL WASTE DUE TO THE USE OF MEDICAL DISPOSABLE ITEMS 3.2.3. RISING USE OF OUTPATIENT TREATMENTS 4. KEY ANALYTICS 4.1. KEY MARKET TRENDS 4.1.1. RISING RATE OF SURGICAL PROCEDURES 4.1.2. EXPANSION OF MINIMALLY INVASIVE AND OUTPATIENT SURGICAL PRACTICES 4.1.3. ADVANCEMENTS IN TECHNOLOGY FOR PREVENTING SURGICAL SITE INFECTIONS 4.2. PORTER’S FIVE FORCES ANALYSIS 4.2.1. BUYERS POWER 4.2.2. SUPPLIERS POWER 4.2.3. SUBSTITUTIONS 4.2.4. NEW ENTRANTS 4.2.5. INDUSTRY RIVALRY 4.3. GROWTH PROSPECT MAPPING FOR GERMANY 4.4. MARKET MATURITY ANALYSIS 4.5. MARKET CONCENTRATION ANALYSIS 5. MARKET BY PROCEDURE 5.1. LAPAROSCOPY 5.2. ORTHOPEDIC SURGERY 5.3. CARDIOVASCULAR 5.4. OBSTETRICS AND GYNECOLOGY 5.5. WOUND CLOSURE 5.6. PLASTIC & RECONSTRUCTIVE SURGERY 5.7. THORACIC SURGERY 5.8. MICROVASCULAR 5.9. UROLOGY 5.10. NEUROSURGERY 5.11. OTHER PROCEDURES 6. MARKET BY TYPE OF INFECTION 6.1. SUPERFICIAL INCISIONAL SSI 6.2. DEEP INCISIONAL SSI 6.3. ORGAN OR SPACE SSI 7. MARKET BY END-USER 7.1. HOSPITALS 7.2. AMBULATORY SURGICAL CENTERS 8. MARKET BY PRODUCT 8.1. DISINFECTANTS 8.1.1. SKIN DISINFECTANTS 8.1.2. HAND DISINFECTANTS 8.2. MANUAL REPROCESSORS SOLUTIONS 8.3. SURGICAL DRAPES 8.4. SURGICAL GLOVES 8.5. SKIN PREPARATION SOLUTIONS 8.6. SURGICAL IRRIGATION 8.7. SURGICAL SCRUBS 8.8. HAIR CLIPPERS 8.9. MEDICAL NONWOVENS 8.10. OTHER PRODUCTS 9. GEOGRAPHICAL ANALYSIS 9.1. EUROPE 9.1.1. MARKET SIZE & ESTIMATES 9.1.2. EUROPE SURGICAL SITE INFECTION CONTROL MARKET DRIVERS 9.1.3. EUROPE SURGICAL SITE INFECTION CONTROL MARKET CHALLENGES 9.1.4. KEY PLAYERS IN EUROPE SURGICAL SITE INFECTION CONTROL MARKET 9.1.5. COUNTRY ANALYSIS 9.1.5.1. UNITED KINGDOM 9.1.5.1.1. UNITED KINGDOM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 9.1.5.2. GERMANY 9.1.5.2.1. GERMANY SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 9.1.5.3. FRANCE 9.1.5.3.1. FRANCE SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 9.1.5.4. ITALY 9.1.5.4.1. ITALY SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 9.1.5.5. SPAIN 9.1.5.5.1. SPAIN SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 9.1.5.6. POLAND 9.1.5.6.1. POLAND SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 9.1.5.7. BELGIUM 9.1.5.7.1. BELGIUM SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 9.1.5.8. REST OF EUROPE 9.1.5.8.1. REST OF EUROPE SURGICAL SITE INFECTION CONTROL MARKET SIZE & OPPORTUNITIES 10. COMPETITIVE LANDSCAPE 10.1. KEY STRATEGIC DEVELOPMENTS 10.1.1. MERGERS & ACQUISITIONS 10.1.2. PARTNERSHIPS & AGREEMENTS 10.1.3. BUSINESS EXPANSIONS & DIVESTITURES 10.2. COMPANY PROFILES 10.2.1. 3M COMPANY 10.2.1.1. COMPANY OVERVIEW 10.2.1.2. PRODUCTS 10.2.1.3. STRENGTHS & CHALLENGES 10.2.2. AMERICAN POLYFILM 10.2.2.1. COMPANY OVERVIEW 10.2.2.2. PRODUCTS 10.2.2.3. STRENGTHS & CHALLENGES 10.2.3. ANSELL LTD 10.2.3.1. COMPANY OVERVIEW 10.2.3.2. PRODUCTS 10.2.3.3. STRENGTHS & CHALLENGES 10.2.4. BECTON, DICKINSON AND COMPANY (BD) 10.2.4.1. COMPANY OVERVIEW 10.2.4.2. PRODUCTS 10.2.4.3. STRENGTHS & CHALLENGES 10.2.5. BELIMED AG 10.2.5.1. COMPANY OVERVIEW 10.2.5.2. PRODUCTS 10.2.5.3. STRENGTHS & CHALLENGES 10.2.6. BIOMERIEUX SA 10.2.6.1. COMPANY OVERVIEW 10.2.6.2. PRODUCTS 10.2.6.3. STRENGTHS & CHALLENGES 10.2.7. GAMA HEALTHCARE 10.2.7.1. COMPANY OVERVIEW 10.2.7.2. PRODUCTS 10.2.7.3. STRENGTHS & CHALLENGES 10.2.8. GETINGE AB 10.2.8.1. COMPANY OVERVIEW 10.2.8.2. PRODUCTS 10.2.8.3. STRENGTHS & CHALLENGES 10.2.9. JOHNSON & JOHNSON 10.2.9.1. COMPANY OVERVIEW 10.2.9.2. PRODUCTS 10.2.9.3. STRENGTHS & CHALLENGES 10.2.10. KIMBERLY-CLARK 10.2.10.1. COMPANY OVERVIEW 10.2.10.2. PRODUCTS 10.2.10.3. STRENGTHS & CHALLENGES 10.2.11. SOTERA HEALTH LLC 10.2.11.1. COMPANY OVERVIEW 10.2.11.2. PRODUCTS 10.2.11.3. STRENGTHS & CHALLENGES 10.2.12. STERIS CORPORATION 10.2.12.1. COMPANY OVERVIEW 10.2.12.2. PRODUCTS 10.2.12.3. STRENGTHS & CHALLENGES 10.2.13. STRYKER CORPORATION 10.2.13.1. COMPANY OVERVIEW 10.2.13.2. PRODUCTS 10.2.13.3. STRENGTHS & CHALLENGES
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
Inkwood Research社のその他分野での最新刊レポート
本レポートと同じKEY WORD(surgical)の最新刊レポート
よくあるご質問Inkwood Research社はどのような調査会社ですか?Inkwood Researchは世界40ヶ国以上の国を対象に広範な市場を調査し、世界市場全体を調査したレポートに加え、アジア太平洋地域、欧州、北米などの主要地域や主要国毎のレポートも数多く出版してい... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|